GLAXO2020-07-012020-09-30in-bse-fin:OneOperatingExpenses01Member GLAXO2020-07-012020-09-30in-bse-fin:FourOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares GLAXO 2020-04-01 2021-03-31 2020-09-28 INR Lakhs Half yearly true Cash Flow Indirect Single segment Pharmaceuticals 2020-07-01 2020-09-30 Unaudited Standalone 8793900000.00 89200000.00 8883100000.00 1456100000.00 2468700000.00 -250100000.00 1540100000.00 8800000.00 219600000.00 1528900000.00 6972100000.00 1911000000.00 -641300000.00 1269700000.00 476100000.00 28600000.00 504700000.00 0.00 765000000.00 0.00 0.00 0.00 0.00 765000000.00 0.00 765000000.00 0.00 0.00 1694100000.00 10 4.52 8.30 0.00 0.00 4.52 8.30 Notes: n1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 28th October, 2020. n2. In accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, the Statutory Auditors have carried out a limited review of the standalone financial results for the quarter ended 30th September, 2020. n3. Exceptional items for the quarter ended 30th September, 2020 of Rs.6413 Lakhs mainly comprise of: nImpact following the decision to initiate a global voluntary recall (pharmacy/retail level) of ranitidine products including Zinetac in India by the Ultimate Holding Company, a comprehensive strategic review of the impact of this recall was undertaken by the Company on all related assets in India including its manufacturing site at Vemgal. After considering all the strategic options available, the Company during the quarter has decided to proceed with the sale of the site and has classified the assets as held for sale. Consequently, the company has recognized financial impact of INR 6413 lakhs to reflect the estimated realizable value of the assets, associated costs and impacts of reversal of provision on account of Zinetac recall. nExceptional items for the quarter ended 30th September, 2019 of Rs. 40114 Lakhs mainly comprise of: na) tGain on sale of land Rs.54519 Lakhs. nb) tCharge on account of impairment of assets Rs.2631 Lakhs. nc) tCharge related to product recall as mentioned above Rs.11074 Lakhs and others Rs.700 Lakhs. Single segment 2020-04-01 2020-09-30 Unaudited Standalone 15280400000.00 667100000.00 15947500000.00 2523300000.00 3952900000.00 -228200000.00 3059300000.00 19600000.00 437300000.00 2779400000.00 12543600000.00 3403900000.00 -641300000.00 2762600000.00 857200000.00 30800000.00 888000000.00 0.00 1874600000.00 0.00 0.00 0.00 0.00 1874600000.00 -30300000.00 1844300000.00 0.00 0.00 1694100000.00 10 11.07 14.85 0.00 0.00 11.07 14.85 Other Expenses 1528900000.00 Other Expenses 2779400000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 641300000.00 0.00 641300000.00 3403900000.00 0.00 0.00 0.00 0.00 -641000000.00 2762900000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4582800000.00 0.00 4582800000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -6870500000.00 -6870500000.00 475200000.00 0.00 475200000.00 980300000.00 1455500000.00